Gastro-intestinal stromal tumour - Role of CD117 in diagnosis and management

Indian Journal of Pathology and Microbiology

Volumn 50, Issue 2, 2007, Pages 279-283

  Paul, Prabir Chandra ^a,d   Chakraborty, Jayati ^b   Kundu, Debabrata ^a   Sarkar, Ranu ^c  

^a MEDICAL COLLEGE AND HOSPITAL   (India)

^b BANKURA SAMMILANI MEDICAL COLLEGE   (India)

^c BANGUR INSTITUTE OF NEUROLOGY   (India)

^d Govt Housing Estate ^*

Author keywords

CD117; GISTs; Immunohistochemistry

Indexed keywords

PROTEIN S 100; SMOOTH MUSCLE ACTIN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE; MALE; MESENTERY; METASTASIS; RETROPERITONEUM; STOMACH;

ACTINS; ADULT; AGED; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-KIT; S100 PROTEINS;

EID: 34548313668     PISSN: 03774929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Chandu de Silva MV, Reid R. Gastro-intestinal stromal tumours: c-kit Mutation, Differential Diagnosis and Targeted Cancer Therapy with Imatinib. Pathol Oncol Research 2003; 9(1): 13-19.
2. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastro-intestinal tumours. Science 1998; 279: 577-80.
3. Vliagoftis H, Worobec AS, Metcalfe DD. The proto-oncogene c-kit and c-kit ligand in human disease. J Alleg Clin Immunol 1997; 100:435-40.
4. Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumours. Science 2003; 299: 708-10.
5. Sarlomo-Rikala M, Koratich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumours that is more specific than CD34. Modern Pathol 1998; 11:728-34.
6. Erlandson RA, Klimstra DS, Woodruff JM. Subclassification of gastrointestinal stromal tumours based on evaluation by electron microscopy and immunohistochemistry. Ultrastruc Pathol 1996; 20:373-94.
7. Fisher C. Gastrointestinal stromal tumours. In: Pignatelli M, Underwood JCE, eds. Recent Advances in Histopathology 21. London: The Royal Society of Medicine Press Ltd, 2005: 71-87.
8. Fletcher CDM, Barman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumours: a consensus approach. Hum Pathol 2002; 33:459-65.
9. Miettinen M, Lasota J. Gastrointestinal stromal tumours - definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchow's Arch 2001; 438:1-12.
10. Cooper PN, Quirke P, Hardy GJ et al. A flow cytometric, clinical and histologic study of stromal neoplasms of the gastrointestinal tract. Am J Surg Path 1992; 16:163-70.
11. West RB, Corless CL Chen X et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumours irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004; 165:107-13.
12. Heinrich MC, Blanke CD, Druker BJ et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-703.
13. Demetri GD, Titton RL, Ryan DP et al. A 68 year old man with a retroperitoneal mass - a case report. N Eng J Med 2004; 351: 1779-87.